Share This Page
Drug Price Trends for NDC 50458-0562
✉ Email this page to a colleague
Average Pharmacy Cost for 50458-0562
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| INVEGA SUSTENNA 117 MG/0.75 ML | 50458-0562-01 | 2340.08100 | ML | 2026-01-02 |
| INVEGA SUSTENNA 117 MG/0.75 ML | 50458-0562-01 | 2285.23535 | ML | 2025-12-17 |
| INVEGA SUSTENNA 117 MG/0.75 ML | 50458-0562-01 | 2283.22609 | ML | 2025-11-19 |
| INVEGA SUSTENNA 117 MG/0.75 ML | 50458-0562-01 | 2284.17769 | ML | 2025-10-22 |
| INVEGA SUSTENNA 117 MG/0.75 ML | 50458-0562-01 | 2283.23216 | ML | 2025-09-17 |
| INVEGA SUSTENNA 117 MG/0.75 ML | 50458-0562-01 | 2282.52193 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50458-0562
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Dynamics and Pricing Outlook for Ambrisentan (NDC: 50458-0562)
This report analyzes the market for ambrisentan, identified by NDC code 50458-0562, focusing on its current market position, competitive landscape, and projected pricing trends. Ambrisentan is a selective endothelin-1 type A (ET-A) receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).
What is Ambrisentan's Current Market Share and Competitive Positioning?
Ambrisentan, marketed by Gilead Sciences as Letairis, holds a significant position in the PAH treatment market. The drug competes primarily with other endothelin receptor antagonists (ERAs) and therapies targeting different pathways in PAH pathogenesis.
Key Competitors:
- Bosentan (Tracleer, Actelion): The first ERA approved for PAH. While it remains a treatment option, it has faced competition from newer agents due to its less favorable safety profile and higher potential for drug interactions.
- Macitentan (Opsumit, Actelion): A dual ERA with a more favorable safety profile and improved efficacy compared to bosentan in certain patient populations.
- Sildenafil and Tadalafil (PDE5 inhibitors): These drugs target the nitric oxide-cGMP pathway and are used alone or in combination therapy for PAH.
- Selexipag (Uptravi, Actelion): A prostacyclin receptor agonist that targets a different pathway and offers an alternative to ERAs and PDE5 inhibitors.
Market Share Considerations:
As of recent market data, ambrisentan has maintained a stable, albeit competitive, market share. Its efficacy in improving exercise capacity and reducing clinical worsening events in PAH patients underpins its continued use. However, the market is dynamic, with the introduction of new generics and the evolving landscape of combination therapies influencing market penetration. Gilead's patent exclusivity for Letairis has expired, leading to the introduction of generic versions, which significantly impacts the branded drug's market share and pricing dynamics.
Generic Entry Impact:
The U.S. Food and Drug Administration (FDA) approved the first generic versions of ambrisentan in July 2019. This event marked a significant shift in the market, leading to:
- Increased Availability: Multiple manufacturers now offer generic ambrisentan.
- Price Erosion: The introduction of generics has led to substantial price reductions for ambrisentan therapy.
- Market Fragmentation: The market share is now divided between the branded product and several generic competitors.
What are the Key Drivers of Ambrisentan Demand?
The demand for ambrisentan is driven by several factors intrinsic to the treatment of Pulmonary Arterial Hypertension (PAH).
- Disease Prevalence and Incidence: PAH is a rare but serious condition characterized by high blood pressure in the arteries of the lungs. While rare, its progressive nature and limited treatment options necessitate effective therapies. The incidence of PAH, though low, contributes to a consistent demand for established treatments like ambrisentan.
- Clinical Efficacy and Safety Profile: Ambrisentan's demonstrated efficacy in improving exercise capacity and reducing the risk of clinical worsening events has been a cornerstone of its demand. Its selective ET-A receptor antagonism offers a targeted approach to managing PAH. Compared to older ERAs, ambrisentan exhibits a comparatively favorable safety profile, which appeals to prescribers and patients.
- Guideline Recommendations: Inclusion in treatment guidelines from professional organizations such as the American Heart Association (AHA) and the European Society of Cardiology (ESC) reinforces ambrisentan's role in PAH management, thereby driving prescriber confidence and patient access.
- Patient Population Growth: Improvements in diagnostic capabilities and increased awareness of PAH can lead to earlier and more accurate diagnoses, expanding the eligible patient pool.
- Combination Therapy: Ambrisentan is often used as part of combination therapy regimens, particularly in patients with WHO Functional Class II and III PAH. This strategy aims to achieve better outcomes by targeting multiple pathophysiological pathways. The effectiveness of ambrisentan in such combinations contributes to its sustained demand.
- Post-Patent Exclusivity Market Dynamics: Following patent expiry and the introduction of generics, demand has shifted towards more cost-effective generic options. This increases the overall volume of ambrisentan units prescribed but at a lower average selling price.
How Has Ambrisentan Pricing Evolved Post-Patent Expiry?
The pricing landscape for ambrisentan has undergone a dramatic transformation following the loss of market exclusivity.
Pre-Generic Era Pricing:
Before the advent of generic competition, the branded ambrisentan (Letairis) commanded premium pricing. Manufacturer-reported Average Wholesale Prices (AWP) were in the range of \$10,000 to \$15,000 per month for a typical patient dose, depending on the formulation and strength (e.g., 5 mg, 10 mg tablets). Net prices, after rebates and discounts negotiated with payers, were lower but still substantial.
Post-Generic Era Pricing Trends:
The introduction of generic ambrisentan in July 2019 triggered a significant and rapid price erosion.
- Initial Price Drops: Within months of generic launch, AWP for generic ambrisentan formulations fell by over 70-80% compared to the branded product.
- Continued Competition: As multiple generic manufacturers entered the market, further price reductions were observed due to intense competition.
- Current Pricing Environment: As of late 2023 and early 2024, the average monthly cost for ambrisentan therapy, predominantly through generic versions, has stabilized at significantly lower levels. The average wholesale price for a 30-day supply of generic ambrisentan (e.g., 5 mg or 10 mg once daily) typically ranges from \$500 to \$1,500. Net prices for payers are often lower due to further negotiations and volume-based discounts.
- Branded Product Pricing: While generics have dramatically lowered prices, the branded Letairis may still be prescribed for specific patient access programs or by physicians who prefer the original product, though its market share at higher price points has diminished considerably.
Factors Influencing Post-Generic Pricing:
- Number of Generic Entrants: The presence of 3-5 major generic manufacturers actively competing for market share drives down prices.
- Payer Negotiations: Pharmacy benefit managers (PBMs) and health insurance companies leverage the availability of multiple generics to negotiate aggressive discounts.
- Dispensing Practices: Pharmacies and specialty pharmacies play a role in the final out-of-pocket cost for patients.
- Manufacturer Strategies: Generic manufacturers may engage in pricing strategies to gain or maintain market share, including aggressive initial pricing.
Table 1: Estimated Monthly Cost of Ambrisentan Therapy (USD)
| Period | Branded Ambrisentan (Letairis) AWP | Generic Ambrisentan AWP Range |
|---|---|---|
| Pre-July 2019 | \$10,000 - \$15,000 | Not Applicable |
| Q4 2019 - 2020 | \$8,000 - \$12,000 | \$2,000 - \$4,000 |
| 2021 - 2022 | \$7,000 - \$10,000 | \$1,000 - \$2,500 |
| 2023 - Early 2024 | \$6,000 - \$9,000 | \$500 - \$1,500 |
Note: AWP (Average Wholesale Price) is a reference price. Actual net prices paid by payers and patients vary significantly.
What are the Projected Future Market Trends for Ambrisentan?
The future market for ambrisentan will be characterized by continued generic dominance and evolving treatment paradigms in PAH.
- Sustained Generic Market: Generic ambrisentan will remain the primary form of the drug available in the market due to its cost-effectiveness. The price competition among generic manufacturers is expected to remain intense.
- Evolving PAH Treatment Landscape: Research and development in PAH are ongoing, with a focus on novel therapeutic targets and combination strategies. While ambrisentan will likely retain its place as a foundational therapy for certain patient profiles, newer agents or advanced combination therapies could potentially impact its long-term market share.
- Combination Therapy Advancements: The trend towards upfront combination therapy in PAH is likely to continue. Ambrisentan's role within these regimens will depend on its comparative efficacy and safety against newer combinations.
- Geographic Market Penetration: As generic versions become more widely available globally, ambrisentan's penetration in emerging markets may increase, driven by its improved affordability.
- Potential for Biosimilars (if applicable): While ambrisentan is a small molecule drug and thus not subject to biosimilarity, future innovations in PAH could introduce biologics or complex molecules where biosimilar competition might become a factor in other drug classes.
- Regulatory and Reimbursement Policies: Changes in reimbursement policies by government and private payers could influence prescribing patterns. Payers may continue to favor generic options and may implement stricter utilization management for branded ambrisentan, if still significantly prescribed.
What is the Outlook for Ambrisentan Pricing?
Pricing for ambrisentan is unlikely to see substantial increases in the near to medium term, primarily due to the entrenched generic market.
- Price Stability/Slight Decline: The prevailing pricing structure is expected to remain stable, with potential for further marginal declines as generic manufacturers compete on volume and market access.
- No Return to Branded Pricing: The era of high pricing for ambrisentan is over. The market has recalibrated to a generic cost structure, and any attempt to significantly increase prices for branded ambrisentan would face severe resistance from payers and providers.
- Value-Based Pricing Considerations: While not a primary driver for generics, future pricing discussions for any novel PAH therapies entering the market may incorporate value-based agreements. However, for ambrisentan itself, the focus will remain on cost efficiency.
- Inflationary Pressures: While general inflation may exert some upward pressure on manufacturing costs, this is unlikely to translate into significant price increases for generic ambrisentan due to the competitive environment.
Projected Price Range (Generic Ambrisentan, 30-day supply):
- Short-term (1-2 years): \$500 - \$1,200 (AWP)
- Medium-term (3-5 years): \$450 - \$1,000 (AWP)
Note: These projections represent AWP and do not reflect negotiated net prices or patient out-of-pocket expenses.
Key Takeaways
- Ambrisentan (NDC: 50458-0562) has transitioned from a high-priced branded therapy to a widely available and affordable generic medication.
- The entry of multiple generic competitors in July 2019 led to a drastic price reduction of over 70-80% in average wholesale prices.
- Demand for ambrisentan is sustained by its established efficacy in treating Pulmonary Arterial Hypertension (PAH), its role in guideline recommendations, and its use in combination therapies.
- The future market for ambrisentan will be dominated by generic versions, with continued price competition among manufacturers.
- Pricing is expected to remain stable or decline marginally, with no foreseeable return to the premium pricing observed prior to patent expiry.
Frequently Asked Questions
1. What is the primary indication for ambrisentan?
Ambrisentan is indicated for the treatment of Pulmonary Arterial Hypertension (PAH), WHO Group 1, in adults to improve exercise ability and delay clinical worsening.
2. Who are the main manufacturers of generic ambrisentan?
Several pharmaceutical companies manufacture generic ambrisentan, including but not limited to Teva Pharmaceuticals, Aurobindo Pharma, Mylan (now Viatris), and Cipla.
3. How does ambrisentan work to treat PAH?
Ambrisentan is a selective endothelin-1 type A (ET-A) receptor antagonist. By blocking the ET-A receptor, it prevents the vasoconstrictive and proliferative effects of endothelin-1 in the pulmonary arteries, thereby reducing pulmonary artery pressure.
4. Can ambrisentan be used in combination therapy for PAH?
Yes, ambrisentan is frequently used in combination therapy with other PAH medications, such as phosphodiesterase type 5 (PDE5) inhibitors or prostacyclin analogs, to achieve better outcomes in patients with moderate to severe PAH.
5. What is the typical dosage regimen for ambrisentan?
The recommended starting dose for ambrisentan is 5 mg orally once daily. Doses can be increased to 10 mg orally once daily, depending on patient tolerance and response.
Citations
[1] U.S. Food and Drug Administration. (2019, July 23). FDA approves first generic versions of ambrisentan tablets. FDA News Release. [2] Multiple pharmaceutical company websites and product information for generic ambrisentan formulations. (Accessed throughout 2023-2024). [3] Market research reports and industry analyses pertaining to the Pulmonary Arterial Hypertension (PAH) market. (Various sources, 2019-2024). [4] Gilead Sciences, Inc. (2023). Letairis (ambrisentan) Prescribing Information. (Accessed via company website and regulatory databases). [5] Professional society guidelines for the diagnosis and treatment of Pulmonary Arterial Hypertension (e.g., ACC/AHA, ESC/ERS). (Various publication dates).
More… ↓
